Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches.

Read it at International Business Times ↗

← Front page